MTI-201 is under clinical development by Modulation Therapeutics and currently in Phase I for Metastatic Uveal Melanoma. According to GlobalData, Phase I drugs for Metastatic Uveal Melanoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MTI-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MTI-201 overview
MTI-201 is under development for the treatment of metastatic uveal melanoma and cutaneous melanoma. The drug candidate is a radioligand therapy, which contains payload of the Actinium 225 alpha particle and acts by targeting melanocyte stimulating hormone receptor (MC1R). It is a cyclic beta-hairpin peptidomimetic. It is administered through intravenous route as solution.
It was under development for the treatment of multiple myeloma.
Modulation Therapeutics overview
Modulation Therapeutics is a clinical-stage biotechnology company. The company provides include the research and development of targeted radio-therapy, small molecule, and peptide-based drug compounds. Its major products include MTI-201 treats uveal melanoma and cutaneous melanoma; MTI-301 to treat triple-negative breast cancer, hepatocellular carcinoma, non-alcoholic steatohepatitis (NASH), and non-alcoholic fatty liver disease; and MTI-101 for the treatment of relapsed multiple myeloma, castrate-resistant prostate cancer, and lung cancer. The company collaborates with various research institutions. Modulation Therapeutics is headquartered in Morgantown, West Virginia, the US.
For a complete picture of MTI-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
